The expression of PDL-1 on tumour cells associated with PD-1 activation on CAR-T led to the hypothesis that blocking this signalling cascade could increase the activation, proliferation, and cytolytic activity of CAR-T cell therapy [70, 71]. The gene discussed is PDCD1; the disease is neoplasm.